论文部分内容阅读
目的观察非小细胞肺癌(NSCLC)中SOX2与survivin的表达情况,探讨它们在NSCLC发生和抗凋亡过程中的作用及相互关系。方法制作67例NSCLC和20例肺良性病变共87例组织的组织芯片,采用免疫组化技术检测SOX2与survivin的表达。结果 1SOX2、survivin在NSCLC中的阳性率分别为74.6%、71.6%,均显著高于肺良性病变组织;2NSCLC中SOX2的阳性率与患者的病理类型、分化程度、淋巴结转移及临床分期有关;survivin的表达与TNM分期有关;3NSCLC中SOX2与survivin的表达呈正相关。结论 SOX2可能参与NSCLC的发生、发展,并通过调节survivin的表达在抗凋亡过程中发挥作用,二者可作为判断NSCLC预后的指标,并很可能成为新的治疗靶点。
Objective To observe the expression of SOX2 and survivin in non-small cell lung cancer (NSCLC) and to explore the role and relationship between SOX2 and survivin in NSCLC. Methods Tissue microarrays were obtained from 87 patients with NSCLC and 20 patients with benign lung lesions. The expressions of SOX2 and survivin were detected by immunohistochemistry. Results The positive rates of 1SOX2 and survivin in NSCLC were 74.6% and 71.6%, respectively, which were significantly higher than those in benign lung tissues. The positive rate of SOX2 in 2 NSCLC was correlated with the pathological type, differentiation degree, lymph node metastasis and clinical stage. Survivin The expression of SOX2 and survivin in 3 NSCLC was positively correlated with the TNM staging. Conclusion SOX2 may play an important role in the development of NSCLC and regulates the expression of survivin in anti-apoptotic NSCLC. Both of them may be used as prognostic indicators in NSCLC and may become new therapeutic targets.